Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
Can-Fite BioPharma (NYSE American: CANF) (TASE: CANF) is hosting an exclusive live investor webinar and Q&A session on October 29, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Motti Farbstein and Executive Chairperson and CSO Dr. Pnina Fishman, who will discuss the company's development pipeline and upcoming milestones.
Can-Fite has multiple out-licensing deals with potential milestone payments exceeding $450 million, having already received $20 million in upfront and milestone payments. The company's advanced-stage assets target unmet medical needs in markets valued at over $70 billion. Investors can register for the free webinar and submit questions in advance or during the live event.
Can-Fite BioPharma (NYSE American: CANF) (TASE: CANF) organizza un webinar esclusivo dal vivo per investitori e una sessione di domande e risposte il 29 ottobre 2024, alle 16:15 ET. L'evento, ospitato da RedChip Companies, presenterà il CEO Motti Farbstein e la Presidente Esecutiva e CSO Dr. Pnina Fishman, che discuteranno del pipeline di sviluppo della società e dei prossimi traguardi.
Can-Fite ha numerosi accordi di licensing con potenziali pagamenti legati a traguardi superiori a 450 milioni di dollari, avendo già ricevuto 20 milioni di dollari in pagamenti iniziali e legati a traguardi. Gli asset in fase avanzata della società puntano a soddisfare esigenze mediche non soddisfatte in mercati valutati oltre 70 miliardi di dollari. Gli investitori possono registrarsi per il webinar gratuito e inviare domande in anticipo o durante l'evento dal vivo.
Can-Fite BioPharma (NYSE American: CANF) (TASE: CANF) está organizando un webinar exclusivo en vivo para inversores y una sesión de preguntas y respuestas el 29 de octubre de 2024 a las 4:15 p.m. ET. El evento, organizado por RedChip Companies, contará con la presencia del CEO Motti Farbstein y la Presidenta Ejecutiva y CSO Dr. Pnina Fishman, quienes discutirán sobre el pipeline de desarrollo de la compañía y los próximos hitos.
Can-Fite tiene Múltiples acuerdos de licenciamiento con pagos potenciales por hitos que superan los 450 millones de dólares, habiendo recibido ya 20 millones de dólares en pagos iniciales y por hitos. Los activos en etapa avanzada de la compañía están dirigidos a necesidades médicas no satisfechas en mercados valorados en más de 70 mil millones de dólares. Los inversores pueden registrarse para el webinar gratuito y enviar preguntas con antelación o durante el evento en vivo.
Can-Fite BioPharma (NYSE American: CANF) (TASE: CANF)는 2024년 10월 29일 오후 4시 15분 ET에 투자자를 위한 독점 라이브 웨비나 및 Q&A 세션을 개최합니다. 이 행사는 RedChip Companies가 주관하며, CEO Motti Farbstein과 의장 겸 CSO Dr. Pnina Fishman이 참여하여 회사의 개발 파이프라인과 다가오는 이정표에 대해 이야기할 것입니다.
Can-Fite는 4억 5천만 달러를 초과하는 잠재적인 이정표 지급이 포함된 여러 아웃 라이센스 계약을 보유하고 있으며, 이미 2천만 달러의 선불 및 이정표 지급을 받았습니다. 이 회사의 고급 자산은 700억 달러 이상의 가치가 있는 시장에서 충족되지 않은 의학적 필요를 겨냥하고 있습니다. 투자자는 무료 웨비나에 등록하고 사전에 또는 라이브 이벤트 중에 질문을 제출할 수 있습니다.
Can-Fite BioPharma (NYSE American: CANF) (TASE: CANF) organise un webinaire exclusif en direct pour les investisseurs et une session de questions-réponses le 29 octobre 2024 à 16h15 ET. L'événement, animé par RedChip Companies, présentera le PDG Motti Farbstein et la Présidente Exécutive et CSO Dr. Pnina Fishman, qui discuteront de la pipeline de développement de l'entreprise et des prochaines étapes importantes.
Can-Fite a plusieurs accords de licence avec des paiements d'étape potentiels dépassant 450 millions de dollars, ayant déjà reçu 20 millions de dollars en paiements initiaux et par étapes. Les actifs en phase avancée de l'entreprise visent à répondre à des besoins médicaux non satisfaits sur des marchés évalués à plus de 70 milliards de dollars. Les investisseurs peuvent s'inscrire au webinaire gratuit et soumettre des questions à l'avance ou pendant l'événement en direct.
Can-Fite BioPharma (NYSE American: CANF) (TASE: CANF) veranstaltet am 29. Oktober 2024 um 16:15 Uhr ET ein exklusives Live-Webinar für Investoren mit einer Q&A-Session. Die Veranstaltung, geleitet von RedChip Companies, wird CEO Motti Farbstein und die Executive Chairperson und CSO Dr. Pnina Fishman präsentieren, die über die Entwicklungspipeline des Unternehmens und bevorstehende Meilensteine sprechen werden.
Can-Fite verfügt über mehrere Lizenzierungsdeals mit potenziellen Meilensteinzahlungen von über 450 Millionen Dollar und hat bereits 20 Millionen Dollar an Voraus- und Meilensteinzahlungen erhalten. Die fortgeschrittenen Vermögenswerte des Unternehmens richten sich an unbefriedigte medizinische Bedürfnisse in Märkten mit einem Wert von über 70 Milliarden Dollar. Investoren können sich für das kostenlose Webinar anmelden und im Voraus oder während der Live-Veranstaltung Fragen stellen.
- Multiple out-licensing deals with potential milestone payments exceeding $450 million
- Already received $20 million in upfront and milestone payments
- Advanced-stage assets targeting markets valued at over $70 billion
- Potential commercialization of innovative therapies
- None.
RAMAT GAN, Israel , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on October 29, 2024, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Can-Fite Chief Executive Officer Motti Farbstein and Executive Chairperson and Chief Scientific Officer Dr. Pnina Fishman, who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential milestone payments totaling over
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_3UZ8u9huRsmIbV216KrdwA#/registration
Questions can be pre-submitted to CANF@redchip.com or online during the live event.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to any resurgence of the COVID-19 pandemic and the war between Israel and Hamas; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 28, 2024 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
Dave Gentry
RedChip Companies, Inc.
CANF@redchip.com
1-407-644-4256
FAQ
When is Can-Fite BioPharma (CANF) hosting its live investor webinar?
Who will be presenting at Can-Fite BioPharma's (CANF) investor webinar?
What is the total potential value of Can-Fite BioPharma's (CANF) out-licensing deals?
How much has Can-Fite BioPharma (CANF) already received in upfront and milestone payments?
